PS1
Not met: no established pathogenic allele produces p.Phe931Ser, and the only codon-931 ClinVar record (240446) is uncertain significance, not pathogenic.
PS2
Not assessed: no proband or parental testing exists, so the confirmed de novo occurrence PS2 requires cannot be evaluated.
PS3
Not assessed: no functional or proofreading assay of POLE p.Phe931Ser was identified, leaving PS3's damaging-effect requirement unevaluable.
PS4
Not met: F931S is absent from Supplementary Table S1 (combined endometrial-cancer count 0, not >=10), so the POLE custom PS4 recurrence rule cannot fire.
PM1
Not met: p.F931S lies outside the POLE exonuclease domain (residues 268-471), where the governing framework restricts PM1 to 14 named hotspot/domain substitutions.
PM3
Not assessed: no trans-partner or phase data exists for heterozygous POLE c.2792T>C, so the recessive in-trans requirement cannot be evaluated.
PM5
Not met: zero codon-931 pathogenic or likely pathogenic comparators exist in ClinVar or the VCEP recurrence/in-silico tables.
PM6
Not assessed: no proband or parental information is reported, so an assumed de novo occurrence cannot be recorded.
PP1
Not assessed: no pedigree, affected relatives, or countable meioses are reported, so co-segregation cannot be scored.
PP2
Not assessed: no POLE-specific PP2 rule and no gene-level missense-constraint data were available to test the criterion.
PP4
Not assessed: no proband phenotype or family history was captured for this case, so phenotype specificity for POLE cannot be evaluated.
PP5
Not met: ClinVar VCV000240446 has zero expert-panel submissions (1-star, conflicting; 3 uncertain, 1 likely benign), so no expert-panel pathogenic assertion supports PP5.
